Business
Pacira BioSciences Reminds Stockholders to Vote the BLUE Proxy Card "FOR" the Election of the Company's Highly Qualified Nominees Ahead of its Annual Meeting
Pacira BioSciences Reminds Stockholders to Vote the BLUE Proxy Card "FOR" the Election of the Company's Highly Qualified Nominees Ahead of its Annual Meeting
About this update from Pacira Biosciences, Inc.
Election of Even a Single DOMA Nominee Would Risk Compromising Pacira's Strong Forward MomentumLeading Independent Experts ISS, Glass Lewis and Egan-Jones Agree that DOMA Representation Is Not WarrantedBRISBANE, Calif., June 4, 2026 /PRNewswire/ -- Pacira BioSciences, Inc. (Nasdaq: PCRX) (the "Company" or "Pacira"), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today issued a reminder to all Pacira stockholders to vote the BLUE proxy card "FOR" each of Pacira's three highly qualified director nominees in advance of the Company's upcoming 2026 Annual Meeting of Stockholders (the "Annual Meeting") on June 9, 2026. Ahead of Pacira's Annual Meeting, stockholders have an important opportunity to safeguard the significant progress Pacira has made by executing its 5x30 strategy to drive sustainable growth and long-term stockholder value. The Company's Board of Directors and management team have positioned Pacira for continued momentum, supported by strong commercial execution, a differentiated non-opioid pain portfolio and a robust and innovative clinical pipeline.Independent third parties, including all three leading proxy advisory firms – ISS, Glass Lewis and Egan-Jones – also recognize Pacira's progress and recommend that Pacira stockholders vote "FOR" each of Pacira's three director nominees – Christopher Christie, Samit Hirawat, MD and Thomas Wiggans – and "AGAINST" all three of DOMA Perpetual Capital Management LLC's ("DOMA Perpetual" or "DOMA")1 nominees on the BLUE proxy card. These recommendations are important third-party endorsements recognizing that Pacira has the right strategy and right board to continue overseeing Pacira's long-term growth and value creation. Here is why:Pacira's focused and highly actionable 5x30 strategy is delivering strong performance, including record financial results, growth across its commercial portfolio and continued advancement of its pipeline. In 2025, Pacira achieved the highest total revenue, GAAP gross margins and non-GAAP gross margins in company history2. Furthermore, in the first quarter of 2026, Pacira achieved EXPAREL revenue of $143.3 million, a 5% increase year-over-year, ZILRETTA revenue of $26.8 million, a 15% increase year-over-year and iovera° revenue of $6.2 million, a 21% increase year-over-year. With respect to our pipeline, w...
View stock analysis, news, and events for Pacira Biosciences, Inc.